Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
By Andrew H. Miller, V. Maletić, Charles L Raison. Biological Psychiatry, 2009
3,746 citations recorded by the source corpus.
Recognition that inflammation may represent a common mechanism of disease has been extended to include neuropsychiatric disorders including major depression. Patients with major depression have been found to exhibit increased peripheral blood inflammatory biomarkers, including inflammatory cytokines, which have been shown to access the brain and interact with virtually every pathophysiologic domain known to be involved in depression, including neurotransmitter metabolism, neuroendocrine function, and neural plasticity. Indeed, activation of inflammatory pathways within the brain is believed to contribute to a confluence of decreased neurotrophic support and altered glutamate release/reuptake, as well as oxidative stress, leading to excitotoxicity and loss of glial elements, consistent with neuropathologic findings that characterize depressive disorders. Further instantiating the link between inflammation and depression are data demonstrating that psychosocial stress, a well-known precipitant of mood disorders, is capable of stimulating inflammatory signaling molecules, including nuclear factor kappa B, in part, through activation of sympathetic nervous system outflow pathways. Interestingly, depressed patients with increased inflammatory biomarkers have been found to be more likely to exhibit treatment resistance, and in several studies, antidepressant therapy has been associated with decreased inflammatory responses. Finally, preliminary data from patients with inflammatory disorders, as well as medically healthy depressed patients, suggest that inhibiting proinflammatory cytokines or their signaling pathways may improve depressed mood and increase treatment response to conventional antidepressant medication. Translational implications of these findings include the unique opportunity to identify relevant patient populations, apply immune-targeted therapies, and monitor therapeutic efficacy at the level of the immune system in addition to behavior.
Subfields: Behavioral Neuroscience, Biological Psychiatry, Social Psychology
View Paper: https://www.semanticscholar.org/paper/3a35e840564ff1b9f616dd537a27b35b5cace508
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Behavioral Neuroscience
- Michael R. Irwin
- Andrew H. Miller
- George M. Slavich
- Gregory E. Miller
- C. Nemeroff
- Charles L Raison
- L. Capuron
- A. Danese
In Biological Psychiatry
- Michael R. Irwin
- Andrew H. Miller
- George M. Slavich
- Charles L Raison
- C. Nemeroff
- Gregory E. Miller
- L. Capuron
- Robin Nusslock
In Social Psychology
- Michael R. Irwin
- Andrew H. Miller
- Charles L Raison
- George M. Slavich
- C. Nemeroff
- L. Capuron
- A. Danese
- E. Haroon
Citations in the corpus
- Inflammation and clinical response to treatment in depression: A meta-analysis. (2015, positive): “An aberrant inflammatory profile has been widely demonstrated in depressive disorders and is believed to contribute to some of the biological mechanisms associated with disease onset and treatment response (Dowlati et al., 2010; Miller et al., 2009; Smith, 1991).”
- Inflammation: The Common Pathway of Stress-Related Diseases (2017, background): “…as cytokines and their soluble receptors, chemokines, acute phase proteins, adhesion molecules and prostaglandins (PGs) have also been found with depression in peripheral blood, CNS and cerebrospinal fluid (CSF; Miller et al., 2009; Dowlati et al., 2010; Norman et al., 2010; Raison et al., 2010).”
- Immune System to Brain Signaling: Neuropsychopharmacological Implications (2011, background): “…Settings The close resemblance of sickness behavior with symptoms of depression has led to the hypothesis that cytokines and inflammatory factors may be involved in the pathophysiology of neuropsychiatric disorders such as depression (Raison et al., 2006; Dantzer et al., 2008; Miller et al., 2009).”
- The Bidirectional Relationship of Depression and Inflammation: Double Trouble (2020, background): “, 2017) that proinflammatory cytokines and acute phase proteins are increased in MDD patients, with a fairly unanimous consensus of increases in IL-6, TNF, and C-reactive protein (CRP) in the blood of MDD patients compared to healthy controls (Maes et al., 2009; Miller et al., 2009; Stewart et al., ”
- Brain-gut interactions in inflammatory bowel disease. (2013, background): “Chronic stress, including caregiving and marital discord, and perceived stress are associated with increases in CRP and other inflammatory mediators (126).”
- Psychoneuroimmunology Meets Neuropsychopharmacology: Translational Implications of the Impact of Inflammation on Behavior (2012, background): “…clinical trials in both patients with malignant melanoma and hepatitis-C have shown that pretreatment with paroxetine can significantly reduce the development of depressive symptoms, especially in patients with elevated symptoms of depression at baseline (Musselman et al, 2001; Raison et al,…”
- Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications (2013, background): “Furthermore, administration of cytokines to humans and laboratory animals produces neuropsychiatric symptoms and behavioral alterations consistent with depression (Miller et al., 2009).”
- From Stress to Inflammation and Major Depressive Disorder: A Social Signal Transduction Theory of Depression (2014, background): “To our knowledge, however, no studies to date have tested for differences in the leukocyte basal transcriptome of depressed versus nondepressed individuals (for related work, see S. W. Cole, 2009, 2010; Fredrickson et al., 2013; A. H. Miller et al., 2009; Pace & Miller, 2009).”